



Press release Montpellier (France), February 20, 2019 - 5:45 pm CET

# Intrasense and 12 Sigma unveil their innovative artificial intelligence solutions at the ECR 2019 congress

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and Myrian® creator, and 12 Sigma Technologies, a pioneer in introducing Artificial Intelligence and deep learning to medical diagnosis and data analysis, announce the presentation of 3 innovative products based on Myrian® technology, at the *European Congress of Radiology* in Vienna (Austria). Partners will also conduct workshops presented by internationally renowned medical professors.

# Artificial Intelligence (AI) into clinical practice

At the ECR – European reference congress of radiology bringing together more than 25.000 participants from February 27 to March 3, 2019 –, Intrasense and 12 Sigma Technologies will present their innovative solutions for the first time on a joint booth, in the dedicated Artificial Intelligence area.

The two partners will launch their latest innovations, putting deep learning and artificial intelligence into clinical workflows. Based on 12 Sigma Technologies algorithms and knowledge and on Intrasense's Myrian® clinical platform and workflow expertise, three new solutions will be presented:

- σ-Discover Lung Nodule, an application developed for lung cancer detection, that revolutionizes the market with its extraordinary thin segmentation and analysis of lung nodules;
- Brand new <u>σ-Discover Lung DR</u>, also an Al-based application for detection of multiple lung diseases;
- and <u>σ-Discover Mammo</u>, a comprehensive Al-based mammogram diagnosis tool.

## Myrian® Studio, an enabler of innovation

By proposing and developing Myrian® Studio, Intrasense encourages development of innovative solutions in medical imaging, providing to start-ups and researchers a ready-to-use solution to industrialize and commercialize their solution very quickly.





# Workshops dedicated to AI technology in oncology

Internationally renowned opinion leaders will also conduct workshops organized by Intrasense and 12 Sigma Technologies during ECR tradeshow:

- Dr Zhengyu JIN Chair at Chinese Society of Radiology and at Department of Radiology, (Peking Union Hospital). Professor at Department of Biomaterial Science (Peking Union Medical College), Chief Editor of Chinese Medical Sciences Journal (China, Beijing) – will present a session about "Al technology improving radiology and oncology";
- Pr. Olivier LUCIDARME Chief of radiology in oncology at La Pitié-Salpêtrière University Hospital (France) will discuss about "Evaluation of tumor response to treatment: advantages or difficulties before Al kicks in."

### **About Intrasense**

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 40 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and invested more than 10 million euros in Research & Development since its creation. More information on www.intrasense.fr.

### **About 12 Sigma Technologies**

Founded in 2015, 12 Sigma Technologies is a pioneer in introducing artificial intelligence and deep learning technologies to modern medicine. The σ-Discover<sup>TM</sup> series, a portfolio of computer aided diagnosis (CAD) products based on AI, have been clinically proven to reduce radiologists' reading time while improving reading accuracy. Partnering with more than 30 top research hospitals across the globe, 12 Sigma has developed CAD products in lung cancer, lung diseases, liver cancer, breast cancer, brain tumors, stroke, bone fracture and more. The σ-Discover<sup>TM</sup> series has been deployed in 200+ healthcare institutions world-wide. Winner of "The 10 Most Innovative AI companies" award by X-techer, 12 Sigma has more than 80 employees in Research and Development, who are located in San Diego, Beijing, Suzhou and Shanghai. For more information, please visit www.12sigma.cn.





### Contacts

Intrasense Nicolas Reymond Chief Executive Officer 1231 avenue du Mondial 11975 El Camino Real, 98, 34000 Montpellier, **FRANCE** 

Tel: +334 67 130 130 investor@intrasense.fr

12 Sigma Technologies Xin Zhong Chief Executive Officer Suite 102, San Diego, CA, 92130, USA Tel: +1 858 412 3455 contact@12sigma.ai

Investor Relations and **Financial Communication** Valentine Brouchot Pierre Laurent

Tel: +331 44 71 94 96 intrasense@newcap.eu

